Clinical utility of inflammatory biomarkers in COVID-19 in direct comparison to other respiratory infections—A prospective cohort study.

MLA

Lampart, Maurin, et al. “Clinical Utility of Inflammatory Biomarkers in COVID-19 in Direct Comparison to Other Respiratory Infections—A Prospective Cohort Study.” PLoS ONE, vol. 17, no. 5, May 2022, pp. 1–20. EBSCOhost, https://doi.org/10.1371/journal.pone.0269005.

APA

Lampart, M., Zellweger, N., Bassetti, S., Tschudin-Sutter, S., Rentsch, K. M., Siegemund, M., Bingisser, R., Osswald, S., Kuster, G. M., & Twerenbold, R. (2022). Clinical utility of inflammatory biomarkers in COVID-19 in direct comparison to other respiratory infections—A prospective cohort study. PLoS ONE, 17(5), 1–20. https://doi.org/10.1371/journal.pone.0269005

Chicago

Lampart, Maurin, Núria Zellweger, Stefano Bassetti, Sarah Tschudin-Sutter, Katharina M. Rentsch, Martin Siegemund, Roland Bingisser, Stefan Osswald, Gabriela M. Kuster, and Raphael Twerenbold. 2022. “Clinical Utility of Inflammatory Biomarkers in COVID-19 in Direct Comparison to Other Respiratory Infections—A Prospective Cohort Study.” PLoS ONE 17 (5): 1–20. doi:10.1371/journal.pone.0269005.